IGF1R and neoplasm: They used a combination of the A12 (anti-IGF-IR) antibody and cetuximab (anti-EGFR) to simultaneously block EGFR and IGF-IR activation, directly blocking the tumorigenic and angiogenic effects of these receptors, resulting in a significant reduction of tumor volume.